- Molecular NameMoxonidine
- SynonymNA
- Weight241.682
- Drugbank_IDN/A
- ACS_NO75438-57-2
- Show 3D model
- LogP (experiment)0.9
- LogP (predicted, AB/LogP v2.0)0.67
- pkaN/A
- LogD (pH=7, predicted)0.32
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-2.06
- LogSw (predicted, AB/LogsW2.0)2.78
- Sw (mg/ml) (predicted, ACD/Labs)0.94
- No.of HBond Donors2
- No.of HBond Acceptors6
- No.of Rotatable Bonds3
- TPSA71.43
- StatusN/A
- AdministrationN/A
- PharmacologyA new generation centrally acting antihypertensive drug licensed for the treatment of mild to moderate essential hypertension. It may have a role when thiazides, beta-blockers, ACE inhibitors and calcium channel blockers are not appropriate or have failed to control blood pressure. In addition, it demonstrates favourable effects on parameters of the insulin resistance syndrome, apparently independent of blood pressure reduction.
- Absorption_value88.0
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability88.0
- Protein binding6.85
- Volume of distribution (VD)1.39 L/kg (0.85 to 1.75 L/kg)
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmN/A
- Half life2~3 h (prolonged in renal impairment).
- ExcretionRenal
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A